

Available online at www.sciencedirect.com

ScienceDirect

www.elsevier.com/locate/brainres

Brain Research



Review

Pathways of polyunsaturated fatty acid utilization: Implications for brain function in neuropsychiatric health and disease[☆]

Q1 Joanne J. Liu^{a,b}, Pnina Green^c, J. John Mann^{a,d,e}, Stanley I. Rapoport^f,
M. Elizabeth Sublette^{a,d,*}

^aDepartment of Molecular Imaging & Neuropathology, New York State Psychiatric Institute, New York, NY, USA

^bNew York Medical College, Valhalla, NY, USA

^cLaboratory of Metabolic Research, Felsenstein Medical Research Center, Tel Aviv University, Petach Tikva, Israel

^dDepartment of Psychiatry, Columbia University, New York, NY, USA

^eDepartment of Radiology, Columbia University, New York, NY, USA

Q2 ^fBrain Physiology and Metabolism Section, Laboratory of Neuroscience, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA

ARTICLE INFO

Article history:

Accepted 27 November 2014

Keywords:

Polyunsaturated fatty acids

Lipid metabolism

Brain

Depression

Bipolar disorder

Schizophrenia

ABSTRACT

Essential polyunsaturated fatty acids (PUFAs) have profound effects on brain development and function. Abnormalities of PUFA status have been implicated in neuropsychiatric diseases such as major depression, bipolar disorder, schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder. Pathophysiologic mechanisms could involve not only suboptimal PUFA intake, but also metabolic and genetic abnormalities, defective hepatic metabolism, and problems with diffusion and transport. This article provides an overview of physiologic factors regulating PUFA utilization, highlighting their relevance to neuropsychiatric disease.

© 2014 Published by Elsevier B.V.

Contents

1. Introduction	2
2. Polyunsaturated fatty acids	3
2.1. Sources of PUFAs	3
2.2. Long-chain PUFA structure and synthesis	3

[☆]**Sources of Support:** This study was supported in part by NIH grant MH079033 (Sublette, PI). The contribution of S. Rapoport was supported entirely by the intramural program of the National Institute on Aging, NIH.

*Correspondence to: New York State Psychiatric Institute, 1051 Riverside Drive, Unit 42, New York, NY 10032, USA.

Fax: +1 646 774 7589.

E-mail address: es2316@columbia.edu (M.E. Sublette).

<http://dx.doi.org/10.1016/j.brainres.2014.11.059>

0006-8993/© 2014 Published by Elsevier B.V.

196	2.3. The balance of n-3 and n-6 PUFAs	4	256
197	2.4. PUFA distribution	5	257
198	2.5. Overview of PUFA functions	5	258
199	3. Digestion, absorption, and secretion of dietary PUFAs	5	259
200	3.1. Oral detection of dietary PUFAs	5	260
201	3.2. Digestion of PUFAs	6	261
202	3.3. Absorption and secretion of PUFAs	6	262
203	4. Peripheral mechanisms of PUFA transport	6	263
204	4.1. Circulating lipoproteins	6	264
205	4.2. Hepatic processing of PUFAs.	6	265
206	4.3. Adipose storage and mobilization of PUFAs.	7	266
207	4.4. PUFA transporters.	7	267
208	5. Brain PUFAs	8	268
209	5.1. Mechanisms of PUFA supply to the brain.	8	269
210	5.1.1. PUFA esterification state during brain uptake	8	270
211	5.1.2. Passive diffusion or protein-facilitated transfer?	9	271
212	5.1.3. Endogenous fatty acid synthesis by the brain	10	272
213	5.1.4. Maintenance of PUFA composition in the brain.	10	273
214	5.1.5. Effects of PUFA balance on brain	10	274
215	5.2. PUFA roles in brain function.	11	275
216	5.2.1. PUFAs and signaling pathways in the brain.	11	276
217	5.2.2. PUFAs and neuroinflammation	11	277
218	5.2.3. PUFAs as regulators of brain energy.	12	278
219	5.2.4. PUFAs and neuroprotection	12	279
220	5.3. Inferring PUFA mechanisms of action from medication effects.	13	280
221	5.4. Relevance of peripheral PUFA biomarker data	13	281
222	6. Conclusions	13	282
223	Funding	14	283
224	Conflicts of interest	14	284
225	References	14	285

1. Introduction

Lipids, which compose cell membranes, occur in very high concentrations throughout the central nervous system (Jumpsen and Clandinin, 1995), making up about half the dry weight of the human brain (Benatti et al., 2004). Of brain lipids, approximately 35% are polyunsaturated fatty acids (PUFAs), which cannot be synthesized de novo from 2-carbon fragments and are nutritionally essential (Benatti et al., 2004). PUFAs are critical for normal brain development and functioning (Luchtman and Song, 2013). They fall into three major categories, according to the number of carbon atoms separating the first double bond of the carbon chain from the terminal methyl (omega) end: n-3, n-6, and n-9. This review will focus primarily on three highly unsaturated, long-chain PUFAs (LC-PUFAs) that appear relevant to neuropsychiatry: arachidonic acid (AA, 20:4n-6) and docosahexaenoic acid (DHA, 22:6n-3), which make up 50% and 40% of brain PUFAs, respectively (Gerster, 1998; Lauritzen et al., 2001; Singh, 2005; Spector, 1999); and eicosapentaenoic acid (EPA, 20:5n-3) (Fernstrom, 1999; McNamara and Strawn, 2013; Youdim et al., 2000; Young and Conquer, 2005), which is maintained at a much lower brain concentration (Chen et al., 2009; Chen et al., 2011) through very rapid breakdown by β -oxidation (Chen and Bazinet, 2014). Also relevant are n-6 and n-3 isomers of docosapentaenoic acid (DPA, 22:5), both of which may serve as a partial substitute for DHA in states of experimental n-3 PUFA deficiency (Kaur et al., 2010; Kaur

et al., 2011; Lim et al., 2005b); and linoleic acid (LA, 18:2n-6) and alpha-linolenic acid (ALA, 18:3n-3), the shorter-chain nutritionally essential precursors of longer-chain n-6 and n-3 PUFAs, respectively.

Lipidomics in neuropsychiatric illness is an emerging field (Wenk, 2005). With respect to LC-PUFA, both AA and DHA are critical to brain development and maintenance of brain structure and function. DHA is important for the health of developing neurons and for neurotransmission, with clear ramifications for cognition and behavior (Innis, 2007). Neurological health also requires sufficient levels of AA for the growth (Darios and Davletov, 2006), repair (Darios and Davletov, 2006), maintenance (Fukaya et al., 2007), and protection (Wang et al., 2006) of neurons. The role of EPA in brain functioning is less clear, but it has been found to be an important component in PUFA supplements for treatment of depression (Lin et al., 2012; Martins, 2009; Martins et al., 2012; Sublette et al., 2011), and EPA status has been specifically associated with certain aspects of substance use disorders (Beier et al., 2014; Buydens-Branchey et al., 2011). Dysregulated lipid metabolism and low dietary consumption of n-3 PUFAs have been implicated in neuropsychiatric diseases, encompassing specific domains including development (Daniels et al., 2004; Gustafsson et al., 2004; Helland et al., 2003; Jorgensen et al., 2001; Larque et al., 2002; Milte et al., 2011; Veena et al., 2010), neurodegeneration (Conquer et al., 2000; Morris et al., 2003; Schaefer et al., 2006), cognition (Barberger-Gateau et al., 2007; Beydoun et al., 2007; Devore et al., 2009; Dullemeijer et al., 2007; Eskelinen et al., 2008;

Download English Version:

<https://daneshyari.com/en/article/6263186>

Download Persian Version:

<https://daneshyari.com/article/6263186>

[Daneshyari.com](https://daneshyari.com)